[go: up one dir, main page]

EA202091120A2 - Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы - Google Patents

Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы

Info

Publication number
EA202091120A2
EA202091120A2 EA202091120A EA202091120A EA202091120A2 EA 202091120 A2 EA202091120 A2 EA 202091120A2 EA 202091120 A EA202091120 A EA 202091120A EA 202091120 A EA202091120 A EA 202091120A EA 202091120 A2 EA202091120 A2 EA 202091120A2
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
nervous system
central nervous
disorders
thiazolinidone
Prior art date
Application number
EA202091120A
Other languages
English (en)
Other versions
EA202091120A3 (ru
Inventor
Ана Мария Гарсия Кольасо
Дэвид Джон Аугустус Экланд
Мария Пилар Пискуэта Лаланса
Марк Мартинель Педемонте
Original Assignee
Минорикс Терапьютикс С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Минорикс Терапьютикс С.Л. filed Critical Минорикс Терапьютикс С.Л.
Publication of EA202091120A2 publication Critical patent/EA202091120A2/ru
Publication of EA202091120A3 publication Critical patent/EA202091120A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к 5-(4-(2-(5-(1-гидроксиэтил)пиридин-2-ил)этокси)бензил)тиазолидин-2,4-диону и новым стереоизомерам указанного соединения для применения в лечении расстройств центральной нервной системы (НС).
EA202091120A 2014-04-02 2015-04-01 Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы EA202091120A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14382130 2014-04-02

Publications (2)

Publication Number Publication Date
EA202091120A2 true EA202091120A2 (ru) 2020-08-31
EA202091120A3 EA202091120A3 (ru) 2020-12-30

Family

ID=50513194

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201691997A EA035866B1 (ru) 2014-04-02 2015-04-01 Применение производных 2,4-тиазолидиндиона для лечения расстройств центральной нервной системы и способ лечения с использованием таких производных
EA202091120A EA202091120A3 (ru) 2014-04-02 2015-04-01 Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201691997A EA035866B1 (ru) 2014-04-02 2015-04-01 Применение производных 2,4-тиазолидиндиона для лечения расстройств центральной нервной системы и способ лечения с использованием таких производных

Country Status (24)

Country Link
US (3) US9782395B2 (ru)
EP (2) EP3125888B1 (ru)
JP (2) JP6745726B2 (ru)
KR (1) KR102418167B1 (ru)
CN (1) CN106470991B (ru)
AU (1) AU2015239112C1 (ru)
CA (1) CA2943373C (ru)
CL (1) CL2016002508A1 (ru)
CY (2) CY1120454T1 (ru)
DK (2) DK3388064T3 (ru)
EA (2) EA035866B1 (ru)
ES (2) ES2872335T3 (ru)
HR (2) HRP20180983T1 (ru)
HU (2) HUE039555T2 (ru)
IL (1) IL248037B (ru)
LT (2) LT3125888T (ru)
MX (1) MX373234B (ru)
NZ (1) NZ725492A (ru)
PL (2) PL3125888T3 (ru)
PT (2) PT3125888T (ru)
SG (1) SG11201608218QA (ru)
SI (2) SI3125888T1 (ru)
WO (1) WO2015150476A1 (ru)
ZA (1) ZA201607286B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3666273A3 (en) 2014-01-15 2020-10-28 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
MX373234B (es) * 2014-04-02 2020-05-08 Minoryx Therapeutics S L Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
JP7040798B2 (ja) 2016-12-01 2022-03-23 ミノリックス セラピューティクス エセ．エレ． 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン
EP3559010B1 (en) * 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
EP3801516A1 (en) * 2018-06-06 2021-04-14 Minoryx Therapeutics S.L. Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
JP7510170B2 (ja) * 2018-06-06 2024-07-03 ミノリックス セラピューティクス エセ．エレ． ５－［［４－［２－［５－アセチルピリジン－２－イル］エトキシ］ベンジル］－１，３－チアゾリジン－２，４－ジオンおよびその塩の使用
FI3801515T3 (fi) 2018-06-06 2025-05-27 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa
IL297771A (en) 2020-04-30 2022-12-01 Minoryx Therapeutics S L Leriglitazone for treating lung inflammation and interstitial lung disease
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
WO2024141951A1 (en) 2022-12-28 2024-07-04 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
WO2024231881A2 (en) 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
SK109993A3 (en) * 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
WO1993022445A1 (en) * 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU2002367154A1 (en) 2001-12-21 2003-07-15 Smithkline Beecham Corporation Dosing regimen for ppar-gamma activators
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
AU2003254146A1 (en) * 2003-07-24 2005-03-07 Case Western Reserve University Methods for the treatment of parkinson's disease
EP2902026B1 (en) 2006-03-16 2017-10-04 Metabolic Solutions Development Company LLC Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
PL2512470T3 (pl) * 2009-12-15 2017-06-30 Octeta Therapeutics, Llc Oszczędzające ppar tiazolidynodiony i połączenia do leczenia chorób neurodegeneracyjnych
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
WO2013040419A1 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) * 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
CA2941562C (en) * 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3666273A3 (en) 2014-01-15 2020-10-28 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
MX373234B (es) * 2014-04-02 2020-05-08 Minoryx Therapeutics S L Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.

Also Published As

Publication number Publication date
NZ725492A (en) 2023-06-30
AU2015239112A1 (en) 2016-11-10
CY1124088T1 (el) 2022-05-27
IL248037B (en) 2020-09-30
PT3125888T (pt) 2018-07-20
LT3125888T (lt) 2018-07-10
EA035866B1 (ru) 2020-08-21
MX373234B (es) 2020-05-08
IL248037A0 (en) 2016-11-30
AU2015239112C1 (en) 2020-08-20
EP3125888A1 (en) 2017-02-08
US9782395B2 (en) 2017-10-10
LT3388064T (lt) 2021-05-25
EP3388064B1 (en) 2021-03-10
US20160235729A1 (en) 2016-08-18
JP6745726B2 (ja) 2020-08-26
BR112016022974A2 (pt) 2017-12-26
ZA201607286B (en) 2021-07-28
US20180133202A1 (en) 2018-05-17
DK3125888T3 (en) 2018-06-25
ES2872335T3 (es) 2021-11-02
EA201691997A1 (ru) 2017-02-28
KR20160145639A (ko) 2016-12-20
CN106470991B (zh) 2020-07-31
HUE055351T2 (hu) 2022-05-28
PL3388064T3 (pl) 2021-07-19
MX2016012687A (es) 2017-04-27
DK3388064T3 (da) 2021-04-19
CY1120454T1 (el) 2019-07-10
CA2943373A1 (en) 2015-10-08
AU2015239112B2 (en) 2020-05-07
CA2943373C (en) 2023-01-10
HUE039555T2 (hu) 2019-01-28
SG11201608218QA (en) 2016-10-28
CN106470991A (zh) 2017-03-01
SI3388064T1 (sl) 2021-08-31
WO2015150476A1 (en) 2015-10-08
EA202091120A3 (ru) 2020-12-30
HRP20210518T1 (hr) 2021-05-14
KR102418167B1 (ko) 2022-07-08
PL3125888T3 (pl) 2018-09-28
JP2020117539A (ja) 2020-08-06
HRP20180983T1 (hr) 2018-08-10
EP3388064A1 (en) 2018-10-17
EP3125888B1 (en) 2018-05-23
SI3125888T1 (en) 2018-08-31
CL2016002508A1 (es) 2017-04-21
JP2017511339A (ja) 2017-04-20
ES2678046T3 (es) 2018-08-08
US20190255032A1 (en) 2019-08-22
US10179126B2 (en) 2019-01-15
PT3388064T (pt) 2021-05-14

Similar Documents

Publication Publication Date Title
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
EA202092442A2 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
MX367918B (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201790271A1 (ru) Ингибиторы гликозидазы
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
RS65437B1 (sr) (r) i (s) enantiomeri n-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oksazol-karboksamida kao inhibitori irak4 za lečenje kancera
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201500362A1 (ru) Ингибиторы rho-киназы
EA201791030A1 (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
MX390051B (es) Antagonistas de ep4.
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
IL257422A (en) (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
EA201790209A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
NZ630803A (en) Optically active pde10 inhibitor
EA202091691A1 (ru) ТВЕРДЫЕ ФОРМЫ ЗАМЕЩЕННЫХ 5,6-ДИГИДРО-6-ФЕНИЛБЕНЗО[f]ИЗОХИНОЛИН-2-АМИНОВЫХ СОЕДИНЕНИЙ